

<b>Report to:</b>	Trust Board
<b>Title of report:</b>	Finance, Service Improvement and Delivery Committee Assurance Report to Board
<b>Date of meeting:</b>	28 February 2017
<b>Status:</b>	For Discussion
<b>Chairperson:</b>	Tim Staniland, Non Executive Director
<b>Author:</b>	Jayne Warner, Trust Secretary

<b>Purpose</b>	This report summarises the assurances received, approvals and decisions made by the Finance, Service Improvement and Delivery Committee (FSID).
<b>Background</b>	This assurance committee meets monthly and takes scheduled reports from all Trust operational committees with a finance planning, estates and performance brief according to an established work programme.
	In light of the deterioration in the Trust's forecast outturn for this financial year, the requirement to present this position at the Quarterly Review Meeting with NHSI on the 8th March the committee agreed to focus the agenda on 2016/17 outturn, 2017/18 plans, Performance Report, Risk Register/ BAF.
<b>1</b>	<p><b>Finance Performance Report 2016/17 Outturn</b></p> <p>The Committee considered a detailed forecast outturn for 2016/17. The Interim Director of Finance highlighted the risk to the planned level of income to the end of March.</p> <p>The Trust had appealed the Q2,Q3 and Q4 STF. The current position builds in loss of the STF for Q4. The Committee asked for clarification on whether Q4 could be appealed if the financial control total was not achieved.</p> <p>The Committee noted that pay costs had been consistent . Agency would not fall as much as was required. More permanent staff were being recruited but agency rates were not falling.</p> <p>The Committee considered the underlying run rate moving in to 2017/18 and concluded that the committee needed to monitor closely the position with this each month.</p> <p>The Committee highlighted the loss of some of the CQUIN money and expected that profiles of this would be shared through the CMB for 2017/18.</p>

	<p>The Committee noted that the cash impact would be managed through creditor payments.</p>
	<p><b>Financial Plan 2017/18</b></p> <p>The Committee considered the 2017/2018 financial plan update. Business plans would be presented to the March meeting.</p> <p>The agreed control total is £48.5m with £14.7m STF.</p> <p>The Committee were alerted to the risks to achieving a plan which met the control total. These were</p> <ul style="list-style-type: none"> <li>• Financial position in the CCGs</li> <li>• Financial consequences of CQC inspection</li> <li>• Non delivery of efficiency programme</li> </ul> <p>The Committee agreed that going forward it would want to see the detail of those areas with the greatest financial challenges and would expect to see the CMB holding the business units to account.</p>
	<p><b>Risk Register/ BAF</b></p> <p>The Committee noted that an external governance review had been commissioned and would commence in March including a review of risk management.</p>
	<p><b>Integrated Performance Report</b></p> <p>The Committee reviewed the integrated performance report.</p> <ul style="list-style-type: none"> <li>• RTT performance in remained static. 7 specialties were being closely monitored with recovery plans.</li> <li>• Diagnostics had achieved Trajectory and continued to be an improving picture.</li> <li>• 62 day – No recovery trajectory aiming for national average. Upper GI. Lower GI and lung are the focus.</li> <li>• A &amp; E – The Trust still continues to underperform against the A &amp; E trajectories. The Trust had sought further external support.</li> <li>• The Trust had met 5 of the 9 cancer standards</li> </ul>
<p><b>Risks to refer to risk register</b></p>	<p>Committee asked the Board to consider escalating the risk ratings for strategic risk SO6.6.1 from 16 to 20.</p>
<p><b>Key decisions taken</b></p>	
<p><b>Issues to escalate to Board</b></p>	<p>The expectation that the Trust would not deliver the 2016/17 control total.</p> <p>The risks to achieving a plan which met the previously agreed control totals for 2017/18.</p> <p>Following the considerations at the meeting the Committee asked the Board to consider escalating the risk ratings for strategic risk SO6.6.1 from</p>

	16 to 20.
<b>Challenges and exceptions</b>	
<b>Future exceptional items</b>	

**Attendance**

***Voting members***

*Tim Staniland, Non Executive Director (Chair)*

*Gill Ponder, Non Executive Director*

*Peter Hollinshead, Interim Director of Finance*

*Mark Brassington, Chief Operating Officer*

***In attendance***

*Neil Morton, Interim Deputy Director of Finance*

*Paul Boocock, Director Estates and Facilities*

*Jan Sobieraj, Chief Executive*

*Jayne Warner, Trust Secretary*